Who is Lindsay Rosenwald?
Dr. Lindsay Rosenwald is a research physician
and biotechnology investor based in New York. He spends much of his
time directly involved with the management of biotechnology
oriented hedge funds.
Rosenwald holds a degree in finance from Penn
State and a Doctor of Medicine degree from Temple University. He
completed his internship at Abington Memorial Hospital and later
ran his own private medical practice. He then shifted his focus to
Wall Street where he worked as a physician/analyst. Notably, Dr.
Lindsay Rosenwald was one of the first physician/analysts in the
country to work on Wall Street.
Dr. Lindsay Rosenwald has founded a number of
biotechnology companies. These companies have licensed more than
100 developmental-stage medicines, many of which have been approved
by the U.S. Food and Drug Administration. Lindsay Rosenwald is
perhaps best known for his role in the development of abiraterone
acetate, a drug that has been used successfully to treat pre-and
post-chemotherapy prostate cancer in the United States. Rosenwald
has also been a key figure in getting drugs approved for infant
respiratory distress syndrome, influenza, fibromyalgia, obesity and
Lindsay Rosenwald founded Cougar
Biotechnology-the company that managed the development and research
of abiraterone acetate. During the early clinical testing phase of
the drug, Cougar Biotechnology was purchased by Johnson &
Johnson for nearly $1 billion. Abiraterone acetate is on target to
become a multibillion-dollar medication in the coming years. Its
trade name is called "Zytiga". Dr. Lindsay Rosenwald is also
credited for the conception of Trisenox, an arsenic trioxide
injection used to promote the remission of acute promyelocytic
In 2009, Rosenwald and his business partner
founded Investment Partnership, a company that invests in life
sciences and health-care companies. Lindsay Rosenwald established
the company on the belief that health care is an ever-changing
field and that returns can be generated by identifying undervalued,
publicly traded biotech companies. For his advancements in the
field of biomedicine, Dr. Rosenwald was featured in 2002's edition
of Genetic Engineering News as No. 1 in its Top 100
Molecular Millionaire lineup.
Throughout his career, the contributions Dr.
Rosenwald has made to medicine have saved thousands of lives and
improved the quality of life for countless more. He has been
significantly involved in founding a number of organizations in the
field including Cypress Biosciences, Javelin Pharmaceuticals,
BioCryst, and Titan Pharmaceuticals. Prior to his current role at
Investment Partnership, Dr. Lindsay Rosenwald held the distinction
of serving as director of Cougar Biotech,and Keryx
Biopharmaceuticals. Dr. Rosenwald serves on the Columbia
Presbyterian Health Sciences Advisory Council.